nonapeptide-1

Nonapeptide-1 (Melanostatine™ 5) can inhibit the synthesis of melanin, which makes it of interest for treating certain skin conditions.

Nonapeptide-1 acetate salt (158563-45-2 free base) (Melanostatine-5 acetate salt) , a peptide hormone, is a potent α-Melanocyte-stimulating hormone (α-MSH) antagonist, with an IC50 of 11 nM. Nonapeptide-1 acetate salt (158563-45-2 free base) , a peptide hormone, is a potent α-Melanocyte-stimulating hormone (α-MSH) antagonist, with an IC50 of 11 nM.

Nonapeptide-1 (Melanostatine-5) acetate salt, a peptide hormone, functions as a selective and competitive antagonist of the melanocortin 1 receptor (MC1R) with a binding affinity (K i) of 40 nM. It effectively inhibits α-MSH-induced increases in intracellular cyclic AMP (cAMP) and melanosome dispersion in melanocytes, showcasing inhibitory concentrations (IC 50) of 2.5 nM and 11 nM, respectively. By inhibiting melanin synthesis, Nonapeptide-1 acetate salt finds application in research related to skin pigmentation, adrenal gland steroid production regulation, and skin cancer [1] [2] [3].

Substance P 1-9 aceate is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder.

p5 Ligand for Dnak and DnaJ acetate is a nonapeptide. It is a high-affinity ligand for DnaK (E. coli Hsp70) and DnaJ (E. coli Hsp40).

TCMCB07, a cyclic nonapeptide, serves as an orally active, brain-penetrant antagonist of the melanocortin receptor 4 (MC4R), with significant implications in the management of cachexia [1].

TPNQRQNVC, a nonapeptide epitope of HLA-B0702, induces a CD8+ T cell immune response [1].

TCMCB07 TFA is a cyclic nonapeptide and an orally active, brain-penetrating antagonist of the melanocortin receptor 4 (MC4R), playing a significant role in managing cachexia [1].

GLP-1(28-36)amide, a C-terminal nonapeptide derived from the cleavage of GLP-1 by neutral endopeptidase (NEP), is a significant product. It functions as an antioxidant and primarily targets the mitochondrion, where it effectively inhibits mitochondrial permeability transition (MPT). This compound exhibits anti-diabetic properties and demonstrates cardioprotection effects[1].

Tyrosinase (192-200), a human mouse nonapeptide, is recognizable by cytolytic T cells (CTL) on the HLA-B44 molecule and is utilized in the research of melanoma-associated cancers [1].

CooP, a linear glioblastoma-targeting nonapeptide, interacts with the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) found in glioblastoma cells and their associated blood vessels. This interaction facilitates the targeted delivery of chemotherapy and various nanoparticles [1].

Substance P (1-9) is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder. Subtance P is responsible for a number of excitatory effects on both central and peripheral neurons.

GLP-1(28-36)amide TFA, a C-terminal nonapeptide derived from GLP-1 cleavage by neutral endopeptidase (NEP), acts as an antioxidant targeting mitochondria. It inhibits mitochondrial permeability transition (MPT), exhibiting anti-diabetic and cardioprotective effects [1].

Hemopressin TFA, a nonapeptide originating from the α1-chain of hemoglobin and initially isolated from rat brain homogenates, is an orally active, selective inverse agonist of CB1 cannabinoid receptors that demonstrates antinociceptive effects in inflammatory pain models [1] [2].

Chemerin-9 (149-157) TFA, the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retains most of the activity of the full-size protein, with regard to agonism toward the chemerinR[1].